Erlotinib hydrochloride pharmaceutical composition without containing surfactant

A technology of erlotinib hydrochloride and surfactant, applied in the field of erlotinib hydrochloride pharmaceutical composition and preparation thereof, can solve the problems of easily destroying the stability of medicinal crystal forms, affecting the stability of products, etc., so as to improve safety sexual effect

Active Publication Date: 2015-01-21
CHENGDU SINO STRONG PHARMA
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This solution is easy to destroy the stability of the pharmaceutical crystal form and affect the stability of the product during the shelf life
[0007] As can be seen from the prior art analysis, its ultimate goal is to improve the dissolution rate of erlotinib hydrochloride in vitro, but each has its own limitations.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Erlotinib hydrochloride pharmaceutical composition without containing surfactant
  • Erlotinib hydrochloride pharmaceutical composition without containing surfactant
  • Erlotinib hydrochloride pharmaceutical composition without containing surfactant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Weigh each component according to prescription 1, mix mannitol, lactose monohydrate and erlotinib hydrochloride evenly and pass through a 60-mesh sieve for micronization. The particle size distribution of the mixed material is required to be D10=0.1~5μm, D50=1~15μm , D90<30 μm. Take the mixture that meets the particle size distribution requirements to monitor the content of erlotinib hydrochloride, and convert the ratio in the material; take the mixture with known solid content, put it in the mixer, add microcrystalline cellulose PH101, sodium starch glycolate and mix for 10 minutes; collect material. Take the mixed material and put it on the dry granulator, adjust the rotation speed of the extrusion wheel (3.6~5.3rpm), the rotation speed of the feeding screw (12~24rpm), the pressure of the oil cylinder (the pressure of the oil cylinder is 1.0 MPa~3.0 MPa) to make it three Those who cooperate effectively, until the hardness of the pressed medicine block (1~3kg) i...

Embodiment 2~5

[0057] Each component is weighed according to prescription 2-5, and the preparation method is the same as in Example 1.

Embodiment 6

[0059] The dissolution rate measurement of embodiment 1~5 preparation

[0060] Dissolution method: paddle method, 75 rpm, solvent: 0.1mol / L hydrochloric acid solution (1%V / V~SDS) 1000ml.

[0061] At 5min, 10min, 15min, 30min, 45min, and 60min, take 10ml and filter it, dilute it with dissolution medium and measure it; the concentration of the reference solution is 10μg / ml. The drug concentration detection method is UV method; the detection wavelength is 352nm. The dissolution data are shown in Table 2.

[0062] Table 2

[0063] .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle size distributionaaaaaaaaaa
Login to view more

Abstract

The invention discloses an erlotinib hydrochloride pharmaceutical composition without containing a surfactant. The erlotinib hydrochloride pharmaceutical composition comprises the following components in parts by weight: 150-300 parts of erlotinib hydrochloride, 40-250 parts of diluents, 80-190 parts of disintegrants and 5-10 parts of lubricants. The invention also provides a preparation method of the pharmaceutical composition. Use of a special auxiliary material of sodium dodecyl sulfate in the composition is rejected, the problem that in vitro dissolution reaches a dissolution platform under special determination conditions is solved simultaneously, the erlotinib hydrochloride pharmaceutical composition is consistent with a reference preparation, in vivo bioavailability is not affected, and the safety of a product in clinical use is improved.

Description

technical field [0001] The invention relates to a surfactant-free erlotinib hydrochloride pharmaceutical composition and a preparation method thereof, belonging to the field of pharmaceutical preparations. Background technique [0002] Erlotinib Hydrochloride (Erlotinib Hydrochloride, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinolinamine hydrochloride, trade name: Tarceva, Tarceva) is a cancer treatment drug developed by OSI Pharmaceuticals in the United States, which belongs to the selective inhibitor of epidermal growth factor tyrosine kinase (EGFR-TK), which selectively blocks human epidermal growth factor receptor tyrosine kinase and reduces EGFR Its autophosphorylation, which leads to cell growth arrest and apoptosis, is mainly used for the treatment of non-small cell lung cancer. In 2005, the FDA approved the combination of erlotinib hydrochloride and gemcitabine for the treatment of advanced pancreatic cancer, becoming the first approved drug for the treatment...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K9/30A61K31/517A61K47/38A61P35/00
Inventor 蒲洪黄汉伟徐杰陈小宁许娟
Owner CHENGDU SINO STRONG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap